Butovsky believes xenon has potential as an AD treatment. A Phase 1 clinical trial of xenon at BWH is recruiting healthy elderly volunteers to test safety and effects on immune cells. “I hope this ...
In vivo perturbations and single-cell RNA-seq reveal cell-type-specific STAT1-IFNg signaling in regulation of trained immunity in tissue-resident immune cells.